Pure Global
NCT06286462

Evaluation of the Cancer Tracking System (CATSystem)

Implementing and Evaluating the Cancer Tracking System (CATSystem): A Systems Level Intervention to Improve Cervical Cancer Screening, Treatment Referral and Follow up in Kenya
University of Kansas Medical Center·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cervical Cancer
Drug/Device/Intervention
Cancer Tracking System (CATSystem)
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
University of Kansas Medical Center
Location
Akala,Bondo,Busia,Busia,Busia,Busia,Busia,Siaya,Siaya,Ukwala, Kenya
Timeline & enrollment
Phase
N/A
Start date
Feb 05, 2024
End date
Jan 31, 2028
Enrollment
6600 participants
Primary outcome

Guideline adherent treatment for a positive screen,Cost-effectiveness of the CATSystem Intervention on screening and treatment outcomes

Summary

Cervical cancer contributes to significant preventable mortality in Kenya where less than 20%
 of women are screened. The Cancer Tracking System (CATSystem) is a web-based, algorithm
 generated tool to promote guideline adherent cervical cancer screening and retention through
 treatment. The goal of this project is to rigorously evaluate the efficacy, implementation,
 and cost-effectiveness of the CATSystem to improve rates of screening, treatment, referral,
 and follow-up care in a matched, cluster randomized controlled trial in 10 Kenyan government
 hospitals (5 intervention, 5 standard of care).

ICD-10 classifications
Severe cervical dysplasia, not elsewhere classifiedMild cervical dysplasiaModerate cervical dysplasiaCarcinoma in situ: Cervix, unspecifiedCervical root disorders, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06286462
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06286462 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Kansas Medical Center and is currently Recruiting. The study focuses on Cervical Cancer. Target enrollment is 6600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.